Munjal Patel - Concepedia

Author

Munjal Patel

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID

Also Known As

Dr. Mineshkumar Uttambhai Patel, M. Patel, M.R. Patel, Maulinkumar Patel, Munjal Patel

Publications

667

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)

About

Munjal Patel is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, hiv, and aids pathogenesis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	79
2	Biomedical Engineering	1	1	65
3	Cell Biology	1	1	14
4	Pathology	1	1	14
5	Cancer Genetics	1	1	14

Munjal Patel

Publications

626

Citations

H-Index

Page 1

	Year	Citations
A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study) Ivan Titov, Richard G. Wunderink, Antoine Roquilly, Clinical Infectious Diseases	2020	213
Effective expansion of alloantigen-specific Foxp3 <sup>+</sup> CD25 <sup>+</sup> CD4 <sup>+</sup> regulatory T cells by dendritic cells during the mixed leukocyte reaction Sayuri Yamazaki, Munjal Patel, A. M. Harper, Proceedings of the National Academy of Sciences	2006	183
Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura Marie Scully, Ana G. Antun, Spero R. Cataland, New England Journal of Medicine	2024	69
Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial Randolph P. Matthews, Munjal Patel, Stephanie E. Barrett, Nature Medicine Islatravir Subdermal ImplantTreatment And PreventionHuman RetrovirusHiv-1 Pre-exposure ProphylaxisAntiviral Therapy	2021	65
Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia Munjal Patel, Francesco Bellanti, Naveen M. Daryani, Clinical and Translational Science	2021	30
Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance Jason A. Roberts, David P. Nicolau, Ignacio Martín‐Loeches, JAC-Antimicrobial Resistance	2023	16
Safety and Pharmacokinetics of Islatravir in Individuals with Severe Renal Insufficiency Randolph P. Matthews, Youfang Cao, Munjal Patel, Antimicrobial Agents and Chemotherapy	2022	15
29LBA Entrectinib (RXDX-101), an oral pan-Trk, ROS1, and ALK inhibitor in patients with advanced solid tumors harboring gene rearrangements Salvatore Siena, Alexander Drilon, I. Ou, European Journal of Cancer Gene RearrangementsMedicinePathologyAdvanced Solid TumorsOral Pan-trk	2015	14
Getting the Dose Right in Drug Development for Rare Diseases: Barriers and Enablers Mariam A. Ahmed, Rajesh Krishna, Noha Rayad, Clinical Pharmacology & Therapeutics	2024	11
Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Children with Confirmed or Suspected Gram‐Negative Bacterial Infections: A Phase 1b, Open‐Label, Single‐Dose Clinical Trial John S. Bradley, Nataliia Makieieva, Camilla Tøndel, The Journal of Clinical Pharmacology	2023	10

Page 1